Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 1321932

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 1321932

Global Nuclear Medicine Market Size, Share, Growth Analysis, By Product type(Diagnostic (SPECT AND PECT), Therapeutic (Alpha Emitters and Beta Emitters)), By Application(Cardiology Neurology, Oncology) - Industry Forecast 2023-2030

PUBLISHED:
PAGES: 157 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
Single User License
USD 5300
Multiple User License
USD 6200
Enterprise License
USD 7100

Add to Cart

Global Nuclear Medicine Market size was valued at USD 8.1 billion in 2021 and is poised to grow from USD 8.9 billion in 2022 to USD 24.4 billion by 2030, growing at a CAGR of 13% in the forecast period (2023-2030).

Nuclear medicine is a specialized field within radiology that utilizes small amounts of radioactive materials to examine organ structure and function. It combines various disciplines such as chemistry, physics, mathematics, computer technology, and medicine. This branch of radiology is particularly valuable in diagnosing and treating diseases at early stages, such as thyroid cancer. While standard X-rays have limitations in visualizing soft tissues, nuclear medicine imaging enables clearer visualization of organs and tissues. The market for nuclear medicine is experiencing growth due to a robust product pipeline and supportive government initiatives aimed at enhancing access to these technologies. Despite the impact of the COVID-19 pandemic, nuclear reactors, which play a critical role in producing essential medicines, have continued operations with stringent safety measures. Prostate cancer is a significant concern, with high incidence rates, particularly among older men. The recent approval of Pluvicto (177Lu-PSMA-617) by the U.S. FDA for the treatment of metastatic prostate cancer further underscores the advancements in nuclear medicine.

Segments covered in this report:

Global nuclear medicine market has been segmented based on product type, application, end use, procedure, and region. Based on product type, global nuclear medicine market are further sub-segmented into diagnostic (SPECT and PET), therapeutic (alpha emitters and beta emitters), and brachytherapy. On the basis of application, global nuclear medicine market is segmented into cardiology neurology, oncology, thyroid, lymphoma, bone metastasis, endocrine tumour, and others. According to end use, global nuclear medicine market is segmented into hospitals & clinics, diagnostic centers and others. By procedure, the market is segmented into central nervous system, endocrine, skeletal, gastrointestinal, genito-urinary, pulmonary. By region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA.

Driver

The increasing incidence and prevalence of cancer and cardiovascular disease are key factors driving the expansion of the nuclear medicine market. These diseases can often be prevented through early detection and treatment, where nuclear medicine plays a crucial role. According to the World Health Organization (WHO), cancer was the leading cause of death in 2020, with an expected rise in new cases worldwide by 2025. Similarly, cardiovascular disease accounted for a significant number of global deaths in 2019, with projections indicating a further increase by 2030. The utilization of nuclear medicine in diagnosing and treating these conditions positions it for significant market growth. Technological advancements in nuclear imaging modalities, particularly PET/PET-CT, have expanded its applications beyond oncology to areas like cardiology, neurology, and infection detection. The increased awareness of the positive impact of early diagnosis and improved disease management further drives market growth, resulting in a rise in PET and SPECT procedures.

Restraint

The growth of the nuclear medicine imaging market is expected to be restrained in the coming years due to the increasing adoption of alternative diagnostic options such as MRI and CT scans. These alternatives are more cost-effective compared to nuclear medicines, leading to their greater use, especially in developing nations. Moreover, reimbursement policies favor the utilization of MRI and CT scans, further hindering the market for nuclear medicine. Additionally, the high cost associated with nuclear imaging systems and procedures, along with the extensive use of CT and MRI scans annually, pose a risk to the volume of PET-CT procedures.

Key Market Trend

The market for nuclear medicine therapies is witnessing a focus on development by companies, driven by the clinical benefits of this treatment option compared to others. The demand for nuclear medicine therapies is expected to rise globally, supported by the positive outcomes observed in the treatment of cancer and other disorders. This is particularly significant in countries with a high cancer burden. For instance, Curium received FDA approval to initiate a Phase-III trial for lutetium Lu 177 PSMA I&T, a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA). Many market participants are also actively developing new therapeutic products for various medical conditions, contributing to the growth of the market.

Product Code: SQMIG35I2126

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Nuclear Medicine Market by Product type

  • Market Overview
  • Diagnostic (SPECT AND PECT)
  • Therapeutic (Alpha Emitters and Beta Emitters)
  • Brachytherapy

Global Nuclear Medicine Market by Application

  • Market Overview
  • Cardiology Neurology
  • Oncology
  • Thyroid
  • Lymphoma
  • Bone Metastasis
  • Endocrine Tumor
  • OthersSegmentEnd-userSub-SegmentsHospitals & Clinics
  • Diagnostic Centers and OthersSegmentProcedureSub-SegmentsCentral Nervous System
  • Endocrine
  • Skeletal
  • Gastrointestinal
  • Genito-urinary
  • Pulmonary

Global Nuclear Medicine Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • GE Healthcare
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Siemens Healthineers
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Philips Healthcare
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Curium Pharma
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cardinal Health
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bracco Imaging
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eckert & Ziegler
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lantheus Medical Imaging
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Jubilant Life Sciences
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nordion Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • IBA Molecular
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Advanced Accelerator Applications (AAA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Progenics Pharmaceuticals
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Norgine B.V.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • FUJIFILM Holdings Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer Healthcare
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Theragnostics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • RadioMedix Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ion Beam Applications S.A. (IBA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!